Literature DB >> 3351480

Antiviral, anti-glycoprotein and neutralizing antibodies in foals with equine infectious anaemia virus.

K O'Rourke1, L E Perryman, T C McGuire.   

Abstract

Equine infectious anaemia virus is related by genome sequence homology to human immunodeficiency virus, caprine arthritis-encephalitis virus and visna virus. Failure of the host to mount a strong neutralizing response detectable in vitro or to eliminate persistent infection in vivo characterizes lentivirus infections in the natural host. In this study the specificities and neutralizing activity of antibodies induced during experimental infection with equine infectious anaemia virus were investigated using antiviral ELISA, radioimmunoprecipitation and neutralization assays. ELISA antibody titres of 10(5) to 10(6) were demonstrated in samples collected 30 and 60 days after infection. Immunoprecipitation titrations demonstrated that antibody titres to the glycoproteins gp90 and gp45 were 10 to 100 times higher than titres to the internal structural protein, p24. Low levels of neutralizing antibody appeared at 23 to 46 days post-infection. The presence of low levels of neutralizing activity in the presence of high levels of anti-glycoprotein activity suggests that the major immunogenic sites on the viral surface are not sensitive to neutralization.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3351480     DOI: 10.1099/0022-1317-69-3-667

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  36 in total

1.  Immune responses and viral replication in long-term inapparent carrier ponies inoculated with equine infectious anemia virus.

Authors:  S A Hammond; F Li; B M McKeon; S J Cook; C J Issel; R C Montelaro
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

2.  CTL from EIAV carrier horses with diverse MHC class I alleles recognize epitope clusters in Gag matrix and capsid proteins.

Authors:  Chungwon Chung; Robert H Mealey; Travis C McGuire
Journal:  Virology       Date:  2004-09-15       Impact factor: 3.616

3.  Selecting peptides to optimize Th1 responses to an equine lentivirus using HLA-DR binding motifs and defined HIV-1 Th peptides.

Authors:  Darrilyn G Fraser; Robert H Mealey; Travis C McGuire
Journal:  Immunogenetics       Date:  2003-08-27       Impact factor: 2.846

4.  cDNA sequence of the env gene of a pathogenic equine infectious anemia lentivirus variant.

Authors:  T C McGuire; P A Lacy; K I O'Rourke
Journal:  Nucleic Acids Res       Date:  1990-01-11       Impact factor: 16.971

5.  Localized sequence heterogeneity in the long terminal repeats of in vivo isolates of equine infectious anemia virus.

Authors:  W Maury; S Perryman; J L Oaks; B K Seid; T Crawford; T McGuire; S Carpenter
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

6.  Viral DNA in horses infected with equine infectious anemia virus.

Authors:  N R Rice; A S Lequarre; J W Casey; S Lahn; R M Stephens; J Edwards
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

7.  Equine infectious anemia virus resists the antiretroviral activity of equine APOBEC3 proteins through a packaging-independent mechanism.

Authors:  Hal P Bogerd; Rebecca L Tallmadge; J Lindsay Oaks; Susan Carpenter; Bryan R Cullen
Journal:  J Virol       Date:  2008-09-25       Impact factor: 5.103

8.  An equine infectious anemia virus variant superinfects cells through novel receptor interactions.

Authors:  Melinda A Brindley; Baoshan Zhang; Ronald C Montelaro; Wendy Maury
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

9.  Proviral sequences detected by polymerase chain reaction in peripheral blood cells of horses with equine infectious anemia lentivirus.

Authors:  K I O'Rourke; M L Besola; T C McGuire
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

10.  Major histocompatibility complex-restricted CD8+ cytotoxic T lymphocytes from horses with equine infectious anemia virus recognize Env and Gag/PR proteins.

Authors:  T C McGuire; D B Tumas; K M Byrne; M T Hines; S R Leib; A L Brassfield; K I O'Rourke; L E Perryman
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.